Cinclus Pharma: Successful completion of IMP manufacturing - Redeye

Redeye leaves a short comment following Cinclus’ recent announcement that the manufacturing of the Investigational Medicinal Product (IMP), to be used for the company's upcoming phase III study of linaprazan glurate for eGERD, has been successfully completed. We are encouraged to learn that the company is following its time plan for the pivotal study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1041284/cinclus-pharma-successful-completion-of-imp-manufacturing?utm_source=finwire&utm_medium=RSS